|
Scientists constructed and tested the chimeric dengue viruses which comprise the prM-E coding region from recent dengue clinical isolates on the genetic background of attenuated virus. Based on promising results from the neurovirulence and immunogenicity testings in mice, the chimeric viruses are considered to have a good potential to be developed further as vaccine candidate for the safety and efficacy studies in non-human primate model. The four serotypes of dengue vaccine candidate were jointly developed by scientists from Chiang Mai University, Mahidol University and Medical Biotechnology Research Unit with research fund from NSTDA.
Four serotypes of chimeric live-attenuated vaccine candidate were licensed to BioNet-Asia Co., Ltd. in February 2011 to further develop into a commercial product.
|
